To study sensitisation to minor histocompatibility antigens (mHag) before and after BMT, we measured antidonor CTL activity in five patients who had rejected their graft, and in a control group of 10 leukemic patients who engrafted without complications. All patients were transplanted with marrow from an HLAidentical sibling. Fourteen patients were conditioned with cyclophosphamide (120 mg/kg) and TBI (1350 cGy) and received a T cell-depleted graft, while one patient with aplastic anaemia received cyclophosphamide alone and unmanipulated marrow. Before transplantation, anti-donor CTL activity was detected in two of the 15 patients. These patients rejected their grafts at days 21 and 58, respectively. In the other three patients who rejected their grafts at days 41, 60 and 250, CTL activity was found only after transplantation. In contrast, no anti-donor CTLs could be detected at any time in the 10 patients who engrafted permanently. We have identified some of the mHags recognised during graft rejection by cloning and subsequent specificity analysis of the recipient CTLs. In the patient who rejected at day 41 without detectable immunisation before BMT, the response was directed against HA-1, a minor antigen known to play a role in GVHD. In the other combinations, a significant part of the CTL activity was directed against the male antigen H-Y. In the patient who rejected the marrow of her HLA-identical brother at day 250, two clones recognised H-Y, while five others recognised at least three distinct autosomal mHags. This patient had an HLA-identical sister who expressed only one autosomal mHag that had been recognised by one single T cell clone. After re-transplantation with the marrow of this second donor, the CTL activity could no longer be detected and the patient engrafted without further complications.
BMT is the only potentially curative therapy for many patients suffering from hematological malignancies or inborn errors of the immune system. [1] [2] [3] However, success is still hindered by GVHD or graft rejection, which represent major causes of post-transplant mortality. [4] [5] [6] When the donor is an HLA genotypically identical sibling and the patient is conditioned with a regimen that contains TBI, the incidence of graft rejection is low. However, when patients are transplanted with T cell-depleted marrow, a technique which effectively prevents GVHD, close to 10% of patients will reject their graft. 7 Rejection is mediated by recipient CTLs that recognise minor histocompatibility antigens (mHags) of the donor. These mHags are transplantation antigens that have recently been characterised as small peptides derived from endogenously synthesised polymorphic proteins which are presented to T lymphocytes by the MHC molecules. 8, 9 Anti-mHag CTL activity can be detected only after in vivo priming. 10 Therefore, sensitisation of donor T cells, cotransfused with the bone marrow or of recipient T cells that have survived conditioning might occur after transplantation. Because of the immunosuppressive effect of the conditioning regimen, the donor alloresponse usually prevails in recipients of unmanipulated grafts, and GVHD caused by donor anti-recipient CTLs occurs more frequently than graft rejection. However, the opposite situation might prevail when the recipient has been previously sensitised to donor histocompatibility antigens, for instance by multiple blood transfusions or pregnancies. [11] [12] [13] [14] To investigate whether such a priming could be detectable before BMT, we tested for pretransplant anti-donor CTL activity in five patients who rejected their graft during the first year following bone marrow transplantation. We found that two of the patients had indeed been pre-sensitised before transplantation, while the others had been primed only after transplantation.
Patients, materials and methods

Selection of patients
Fifteen patients transplanted with an HLA genotypically identical bone marrow, of which five patients had rejected their graft between 21 and 250 days after transplantation, were included in this study. The sibling pairs were matched by serotyping for HLA-A, B and by oligotyping for HLA-DR 1-14. 15 For the five patients who had rejected their graft, further high resolution DR/DQ-typing discriminating the vast majority of HLA-DR and -DQ genes, and high resolution HLA class I oligotyping for HLA-A2, -A3, -B44 and -B35 were performed as described previously. [16] [17] [18] HLA-C oligotyping was performed essentially according to Kennedy et al. 19 Diagnoses, conditioning, GVHD prophylaxis and occurrence of graft rejection are depicted in Table 1 .
Detection and cloning of donor specific T cells before and after transplantation
All the procedures used have been described previously. 20 In brief, peripheral blood samples were collected from donor and patient before and after transplantation, separated by Ficoll-Paque and cryopreserved. On day 3 and 6, 25 l of fresh medium containing 100 U/ml rIL-2 (Roche, Nutley, NJ, USA) was added to all wells. After 10 days culture, the wells were tested for activity against 51 Crlabeled phytohaemagglutinin (PHA)-stimulated donor T cell blasts.
Cytotoxic T cell clones were established from the positive wells of the CTL assays as described previously 21 and specificity towards donor cells was tested by including autologous recipient cells and third-party cells which did not express HLA antigens in common with the donor as negative controls. Further specificity testing was performed against a panel of cells expressing well characterised HLA-A, -B, and -C antigens.
Typing of mHag HA-1
Expression of HA-1 was determined by measuring the lysis of 51 Cr-labeled PHA-blasts by the HA-1 specific T cell clones. In addition, a selected panel of target cells express- TBI, CTX CsA, C1M/1G None MDS = myelodysplastic syndrome; ALL = acute lymphoblastic leukaemia; AML = acute myelogenous leukaemia; CML = chronic myelogenous leukaemia; SAA = severe aplastic anaemia; TBI = fractionated total body irradiation; TLI = total lymphoid irradiation including the spleen; CTX = cyclophosphamide; CsA = cyclosporin A; C1M = Campath-1M; C1G = Campath-1G; MTX = methotrexate. ing mHags HA-1 and H-Y was used to determine the specificity of the pre-and post-transplant clones.
22,23
Results
Sensitisation towards mHags before and after bone marrow transplantation
We have studied five patients who had rejected the marrow from an HLA genotypically identical donor and a control group of 10 patients who engrafted durably. Fourteen of the 15 patients, transplanted for either myelodysplatic syndrome, acute lymphoblastic myelogenous leukaemia or for chronic myelogenous leukaemia received T cell-depleted marrow after conditioning with a regimen including total body irradiation (TBI, 1350 cGy). Patient 5, who suffered from severe aplastic anaemia, received an unmanipulated marrow and a conditioning regimen without TBI (Table 1) . Pre-and post-transplant recipient anti-donor cytotoxic activity was measured by cytotoxic T lymphocyte precursor frequency analysis (CTLpf). Whereas no anti-donor CTLs could be found in the control group, pretransplant antidonor CTL activity was detected in two of the five patients (patients 1 and 3) who rejected their graft after 21 and 58 days, respectively. In the other three patients, who rejected their grafts after 41, 60 and 250 days, CTL activity was found only after transplantation (Table 2) . To study which incompatibilities were recognised during graft rejection, we analysed the specificity of donor CD8 + T cell clones that were isolated from the positive wells of the cytotoxic assays. In three of the four sex-mismatched combinations, a significant part of the response was directed against H-Y. In patient 2, who rejected after 41 days without being immunised before BMT, the CTL response was directed exclusively against HA-1, the HLA-A‫-1020ء‬restricted mHag frequently recognized. 23, 24 All other specificities recognised by the CTL that were assumed to recognise the same mHag when they lysed the same panel cells were designated as minor I-III (Table 2) . Three CTL clones with anti-donor activity were not further characterised.
A successful second transplant with marrow from a donor expressing only one mHag recognised during the previous rejection
Two of the five patients (patients 2 and 5) were re-transplanted. Patient 2, who had rejected the graft of her brother was transplanted with the marrow of an HLA-identical sister. Graft failure ensued and the patient died with pancytopenia. As the second donor also expressed the mHag HA-1 against which all the CTL activity had been directed during the first rejection (Table 3) , it is likely that the second rejection, that occurred very rapidly, was caused by the sensitisation that had occurred during the first transplantation. For patient 5, the situation was entirely different: of the seven clones that were isolated after the rejection of the marrow of her brother, only one recognised the cells of the other (female) HLA-identical sibling. After a second transplant was performed, resulting in durable engraftment, no further donor-specific CTLs was detected. Table 2 , footnote 4).
Discussion
We have investigated the role of immunisation towards mHags in five patients who rejected their graft during the first year after BMT. In two of these patients, we were able to detect a significant anti-donor CTL activity before transplantation. In the other three patients, CTL activity was found only after rejection, while such activity was never found in a control group of 10 patients who engrafted without complications. It has been reported that in patients with severe aplastic anaemia, pretransplant anti-donor activity is frequently detected and that this could explain the relatively high risk of graft rejection in this group. 13 From our data, we cannot precisely estimate the frequency of the occurrence of anti-donor CTLs in patients with other haematological diseases, because in our series, patients who had rejected their grafts were highly overrepresented. However, our data do show that pretransplant immunisation against mHags does occur in leukaemic patients, and that these patients are at high risk of graft rejection. Unfortunately, we were not able to identify a reason why these two patients were immunised against mHags in particular. Although these patients had received multiple blood transfusions, the number was not significantly higher than in the control group (data not shown). Because some of the patients without pretransplant CTLs had received more than 50 transfusions, it appears that the chance of being immunised against mHags by a blood transfusion is rather low. One could argue, that as long as blood transfusions are not HLA-matched to a high degree, the patient will be immunised only against the incompatible major histocompatibility antigens that will act as immunodominant epitopes. Therefore, most of the mHags expressed by the blood donor might be simply ignored and immunisation against mHags might only occur by a transfusion that expresses a high number of 'right' MHC-molecules and 'wrong' mHags. The finding that the CTLs responsible for the rejection were directed against a very limited number of mHags reflects the fact that allogeneic responses in matched siblings are usually directed to a few epitopes only. Although most donor recipient pairs were probably incompatible for numerous mHags, only seven different mHags were recognised in these patients. The fact that the anti-mHag response of the CTLs responsible for rejection is so restricted, does facilitate another transplant when the second donor does not express the same mHags. This is illustrated by two cases in this report. One patient rejected her graft, while all CTLs were directed against HA-1, a mHag also expressed by the second donor. As a consequence, graft failure occurred very rapidly and the patient died with pancytopenia. In contrast, the response during the rejection in another patient was directed predominantly against mHags which were not expressed by the second donor. Re-transplantation in this patient was successful and no further antidonor CTLs were detected.
In conclusion, we believe that in the field of stem cell transplantation, cytotoxic assays and analysis by specific CTL clones are very useful laboratory tools, since they allow the detection of sensitisation towards mHags, plus typing of alternative donors for the expression of the mHags recognised during a first rejection. Therefore, this type of analysis could be performed when more than one compatible donor is available in the patient's family, or in the international registries of unrelated donors.
